Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mdm2: p53's lifesaver?

Ayelet Shmueli1, Moshe Oren

  • 1Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot 76100, Israel.

Molecular Cell
|March 28, 2007
PubMed
Summary
This summary is machine-generated.

Two studies reveal how DYRK2 kinase and MDM2 regulate DNA damage-induced apoptosis through p53 phosphorylation, offering new insights into cellular stress responses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A microRNA generated via lysosomal processing of ribosomal RNA suppresses proinflammatory responses.

Life science alliance·2026
Same author

Activated T cell extracellular vesicle DNA transfer enhances antigen presentation and anti-tumor immunity.

Cancer cell·2026
Same author

GLYATL1 is associated with metabolic and epigenetic changes and with endocrine resistance in luminal breast cancer.

Clinical epigenetics·2026
Same author

p53 regulates the expression of histone modifiers to restrict stemness and maintain differentiated luminal identity in breast cancer.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

The legacy of a gentleman scientist: Pierre Hainaut.

Cell death and differentiation·2025
Same author

Sensitizing Immune-Refractory Ovarian Tumors via p53 Mutation-Tailored Immunotherapy.

bioRxiv : the preprint server for biology·2025
Same journal

Thyroid cancer-associated EZH1 Q571R mutation drives chromatin compaction and H3K27me3 invasion into active chromatin.

Molecular cell·2026
Same journal

Genome-wide rotational and translational phasing of nucleosomes with human transcription factors.

Molecular cell·2026
Same journal

Spliceosomal proofreading factors safeguard 3' splice-site fidelity and prevent proteotoxicity and inflammation.

Molecular cell·2026
Same journal

Cytosolic EZH2-IMPDH2 complexes regulate melanoma progression and metastasis via GTP.

Molecular cell·2026
Same journal

A bacterial reverse transcriptase: Protein-templated DNA synthesis fuels antiviral immunity.

Molecular cell·2026
Same journal

Tweezing apart ribosome heterogeneity.

Molecular cell·2026
See all related articles

Area of Science:

  • Cellular biology
  • Molecular oncology
  • Biochemistry

Background:

  • DNA damage response pathways are crucial for maintaining genomic stability.
  • Apoptosis, or programmed cell death, is a key mechanism for eliminating damaged cells.
  • The p53 tumor suppressor protein plays a central role in coordinating cellular responses to DNA damage.

Purpose of the Study:

  • To elucidate the molecular mechanisms regulating DNA damage-induced apoptosis.
  • To investigate the role of DYRK2 kinase in p53 phosphorylation.
  • To explore the involvement of MDM2 in the p53-mediated apoptotic pathway.

Main Methods:

  • Western blotting to detect protein phosphorylation.
  • Immunoprecipitation assays to study protein interactions.

Related Experiment Videos

  • Cell-based assays to measure apoptosis induction.

    • Main Results:

    • DYRK2 kinase directly phosphorylates p53 at specific sites.
    • MDM2, a known E3 ubiquitin ligase, surprisingly promotes p53 phosphorylation in response to DNA damage.
    • p53 phosphorylation by DYRK2 and MDM2 enhances its pro-apoptotic function.

    Conclusions:

    • DYRK2 and MDM2 are key regulators of p53-dependent apoptosis following DNA damage.
    • These findings uncover a novel regulatory axis involving MDM2 in p53 activation.
    • Targeting DYRK2 or MDM2 may offer therapeutic strategies for cancer treatment.